Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Business Wire•20/11/2026•06:45 ET
0
Key Highlights
- ➤TroFuse-015 met its primary overall-survival endpoint versus physician’s choice in third-line gastroesophageal cancer
- ➤Sac-TMT became the first TROP2 ADC to improve overall survival in this global Phase 3 population
- ➤Sac-TMT failed to meet the secondary progression-free-survival endpoint assessed by blinded independent review
- ➤TroFuse program includes 18 ongoing global Phase 3 trials across multiple tumor types
- ➤TroFuse-015 enrolled 473 patients receiving sac-TMT or trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel
Expert Statements
Dr. Marjorie Green, Senior vice president and head of oncology, global clinical development, Merck Research Laboratories
“Sac-TMT is the first TROP2 ADC to improve OS in a global Phase 3 study in advanced gastroesophageal adenocarcinoma compared to TPC, demonstrating its potential in a particularly challenging disease setting.”
Dr. Marjorie Green, Senior vice president and head of oncology, global clinical development, Merck Research Laboratories
“There is a tremendous unmet need for therapies that can improve survival for these patients. We look forward to discussing these data with regulatory authorities and sharing with the scientific community on behalf of patients who may benefit.”
Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Sac-TMT is the first TROP2 ADC to improve OS compared to treatment of physician’s choice (TPC) in patients with advanced gastroesophageal adenocarcinoma who have received two or more prior lines of systemic therapy in a global Phase 3 study
Get started
Create a free account to read the full story.
